Granulomatosis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2019–2025)

“GervanoRA’s Market Estimation report “Granulomatosis: Opportunity Assessments, Epidemiology Forecast, Market Dynamics, Pipeline Analysis, Current Market Size and Market Forecast (2019–2025)” analyzed the current and upcoming opportunities in the Granulomatosis area by assessing the drug market, covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Granulomatosis industry. The report has been divided into segments like Disease Overview, Market Overview, Pipeline Analysis and Clinical Trials summary to provide in depth insights about the market dynamics and ongoing R&D in the Granulomatosis area. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development. The report evaluated the current market scenario by estimating the market value with respect to Granulomatosis Drug Class, Route of Administration and Age Group. Report primarily focuses on the patent analysis of the key marketed and pipeline drugs to provide a brief understanding about the market opportunities in the Granulomatosis competitive environment. We have also prognosticated the Granulomatosis market share in 11 Major Markets to aid our clients with the commercial and economic opportunities in these geographies.
Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on
• Epidemiology and Epidemiology forecast 2019 – 2025
• Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
• Estimated Pipeline Drug Approval Timelines
• Clinical Trials Summary
• Current and Future Competitive Landscape
• Key Company Profiles with SWOT Analysis
• Emerging Company Profiles with Opportunity Assessments
• Pipeline Drug Descriptions along with Development milestones (Past and Future)
• University Pipeline Molecules & In-Licensing/Out Licensing Opportunities.”

“TABLE OF CONTENTS
1. INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. METHODOLOGY
1.3. UPCOMING AND OTHER AVAILABLE REPORTS
1.4. ABOUT US: GERVANORA DATA SERVICES
2. EXECUTIVE SUMMARY
2.1. MARKET SNAPSHOT, 2019-2025
2.2. KEY EVENTS IN GRANULOMATOSIS MARKET, 2015-2030
2.3. PRODUCT LIFE CYCLE MANAGEMENT (LCM) STRATEGIES
2.4. KEY MAJOR FINDINGS
2.4.1. DRIVERS
2.4.2. RESTRAINTS
2.4.1. UNMET NEEDS AND OPPORTUNITIES
3. DISEASE OVERVIEW
3.1. DISEASE DEFINITION & SYMPTOMS
3.1.1. CLINICAL MANIFESTATIONS
3.1.2. PATHOGENESIS
3.2. DISEASE CAUSE AND CLASSIFICATION
3.3. DISEASE DIAGNOSIS
3.4. TREATMENT ALGORITHM AND GUIDELINES
3.5. EPIDEMIOLOGY AND DISEASE BURDEN
3.6. EPIDEMIOLOGY FORECAST
3.6.1. FORECAST METHODOLOGY AND ASSUMPTION
3.6.2. PROBABILISTIC EPIDEMIOLOGY FORECAST
4. MARKET OVERVIEW
4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
4.2. PRICING AND REIMBURSEMENT
4.3. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
4.4. NEW DRUG APPROVALS (US FDA) SINCE 2010
4.5. NEW DRUG APPROVALS (EMA) SINCE 2010
4.6. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)
5. PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE
5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
5.1.1. PRE-REGISTRATION (FILED) MOLECULES
5.1.2. PHASE 3 MOLECULES
5.1.3. PHASE 2 MOLECULES
5.1.4. PHASE 1 MOLECULES
5.1.5. PRECLINICAL MOLECULES
5.1.6. EARLY R&D MOLECULES
5.1.7. INACTIVE AND TERMINATED MOLECULES
5.2. PIPELINE ANALYSIS BY GEOGRAPHY
5.2.1. UNMET NEEDS AND OPPORTUNITIES
5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
5.3.1. UNMET NEEDS AND OPPORTUNITIES
5.4. PIPELINE ANALYSIS BY DRUG CLASS
5.4.1. UNMET NEEDS AND OPPORTUNITIES
5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
5.5.1. UNMET NEEDS AND OPPORTUNITIES
5.6 PIPELINE ANALYSIS BY UNIVERSITIES AND INSTITUTES
5.7. ESTIMATED APPROVAL TIMELINES
5.7.1. METHODOLOGY
5.7.2. ESTIMATED APPROVAL TIMELINES US & EX-US
6. GRANULOMATOSIS CLINICAL TRIALS SUMMARY
6.1. GRANULOMATOSIS PIPELINE ANALYSIS BY CLINICAL TRIALS RESULTS
6.1.1. KEY PHASE 3 RESULTS
6.1.2. KEY PHASE 2 RESULTS
6.2. ONGOING CLINICAL TRIALS SUMMARY
6.2.1. KEY PHASE 3 ONGOING CLINICAL TRIALS SUMMARY
6.2.2. KEY PHASE 2 ONGOING CLINICAL TRIALS SUMMARY
6.2.3. KEY PHASE 1 ONGOING CLINICAL TRIALS SUMMARY
6.3 PLANNED CLINICAL TRIALS SUMMARY
6.4. RECENTLY COMPLETED CLINICAL TRIALS SUMMARY
6.4.1. RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS SUMMARY
6.4.2. RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS SUMMARY
6.4.3. RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS SUMMARY
7. GRANULOMATOSIS MARKET BY DRUG CLASS
8. GRANULOMATOSIS MARKET BY ROUTE OF ADMINISTRATION
9. GRANULOMATOSIS MARKET BY GEOGRAPHY
9.1. UNITED STATES
9.1.1. MARKET TRENDS AND GROWTH FACTORS
9.1.2. UNMET NEEDS AND OPPORTUNITIES
9.1.3. US GRANULOMATOSIS MARKET SIZE (2018), FORECAST (2019-2025)
9.2. UNITED KINGDOM
9.2.1. MARKET TRENDS AND GROWTH FACTORS
9.2.2. UNMET NEEDS AND OPPORTUNITIES
9.2.3. UK GRANULOMATOSIS MARKET SIZE (2018), FORECAST (2019-2025)
9.3. GERMANY
9.3.1. MARKET TRENDS AND GROWTH FACTORS
9.3.2. GERMANY GRANULOMATOSIS MARKET SIZE (2018), FORECAST (2019-2025)
9.4. FRANCE
9.4.1. MARKET TRENDS AND GROWTH FACTORS
9.4.2. UNMET NEEDS AND OPPORTUNITIES
9.4.3. FRANCE GRANULOMATOSIS MARKET SIZE (2018), FORECAST (2019-2025)
9.5. ITALY
9.5.1. MARKET TRENDS AND GROWTH FACTORS
9.5.2. UNMET NEEDS AND OPPORTUNITIES
9.5.3. ITALY GRANULOMATOSIS MARKET SIZE (2018), FORECAST (2019-2025)
9.6. SPAIN
9.6.1. MARKET TRENDS AND GROWTH FACTORS
9.6.2. UNMET NEEDS AND OPPORTUNITIES
9.6.3. SPAIN GRANULOMATOSIS MARKET SIZE (2018), FORECAST (2019-2025)
9.7. JAPAN
9.7.1. MARKET TRENDS AND GROWTH FACTORS
9.7.2. UNMET NEEDS AND OPPORTUNITIES
9.7.3. JAPAN GRANULOMATOSIS MARKET SIZE (2018), FORECAST (2019-2025)
9.8. CHINA
9.8.1. MARKET TRENDS AND GROWTH FACTORS
9.8.2. UNMET NEEDS AND OPPORTUNITIES
9.8.3. CHINA GRANULOMATOSIS MARKET SIZE (2018), FORECAST (2019-2025)
9.9. INDIA
9.9.1. MARKET TRENDS AND GROWTH FACTORS
9.9.2. UNMET NEEDS AND OPPORTUNITIES
9.9.3. INDIA GRANULOMATOSIS MARKET SIZE (2018), FORECAST (2019-2025)
9.10. BRAZIL
9.10.1. MARKET TRENDS AND GROWTH FACTORS
9.10.2. UNMET NEEDS AND OPPORTUNITIES
9.10.3. BRAZIL GRANULOMATOSIS MARKET SIZE (2018), FORECAST (2019-2025)
9.11. RUSSIA
9.11.1. MARKET TRENDS AND GROWTH FACTORS
9.11.2. UNMET NEEDS AND OPPORTUNITIES
9.11.3. RUSSIA GRANULOMATOSIS MARKET SIZE (2018), FORECAST (2019-2025)
9.12. ROW
9.12.1. MARKET TRENDS AND GROWTH FACTORS
9.12.2. UNMET NEEDS AND OPPORTUNITIES
9.12.3. ROW MARKET SIZE (2018), FORECAST (2019-2025)
10. CURRENT AND FUTURE COMPETITIVE LANDSCAPE
10.1. COMPANIES
10.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
10.1.2. TOP 20 EMERGING COMPANIES IN THE GRANULOMATOSIS AREA
10.2. UNIVERSITIES AND INSTITUTES
11. ABBREVIATIONS
LIST OF TABLES:
TABLE 1: REPORT HIGHLIGHTS IN NUMERICALS
TABLE 2: LIST OF FDA APPROVED DRUGS FOR GRANULOMATOSIS
TABLE 3: LIST OF EMA APPROVED DRUGS FOR GRANULOMATOSIS
TABLE 4: GRANULOMATOSIS EPIDEMIOLOGY (2018), FORECAST (2019-2025)
TABLE 5: MAJOR ACQUISITIONS AND MERGERS IN GRANULOMATOSIS AREA
TABLE 6: MAJOR COLLABORATIVE AGREEMENTS IN GRANULOMATOSIS AREA
TABLE 7: MAJOR LICENSING AGREEMENTS IN GRANULOMATOSIS AREA
TABLE 8: MAJOR PARTNERSHIPS AND JOINT VENTURE IN GRANULOMATOSIS AREA
TABLE 9: MAJOR GRANTS AND FUNDINGS IN GRANULOMATOSIS AREA
TABLE 10: MAJOR ALLIANCE DEALS IN GRANULOMATOSIS AREA
TABLE 11: US FDA APPROVED DRUGS FOR GRANULOMATOSIS SINCE 2010
TABLE 12: EX-US APPROVED DRUGS FOR GRANULOMATOSIS SINCE 2010
TABLE 13: PRE-REGISTRATION (FILED) MOLECULES IN THE GRANULOMATOSIS DRUG PIPELINE
TABLE 14: PHASE 3 MOLECULES IN THE GRANULOMATOSIS DRUG PIPELINE
TABLE 15: PHASE 2 MOLECULES IN THE GRANULOMATOSIS DRUG PIPELINE
TABLE 16: PHASE 1 MOLECULES IN THE GRANULOMATOSIS DRUG PIPELINE
TABLE 17: PRECLINICAL MOLECULES IN THE GRANULOMATOSIS DRUG PIPELINE
TABLE 18: EARLY R&D MOLECULES IN THE GRANULOMATOSIS DRUG PIPELINE
TABLE 19: TERMINATED AND INACTIVE MOLECULES IN THE GRANULOMATOSIS DRUG PIPELINE
TABLE 20: GRANULOMATOSIS DRUG PIPELINE MOLECULES BY ROUTE OF ADMINISTRATION
TABLE 21: GRANULOMATOSIS DRUG PIPELINE MOLECULES OVERVIEW BY DRUG CLASS
TABLE 22: GRANULOMATOSIS DRUG PIPELINE MOLECULES BY UNIVERSITIES
TABLE 23: GRANULOMATOSIS DRUG PIPELINE MOLECULES BY INSTITUTES
TABLE 24: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
TABLE 25: KEY PHASE 3 ONGOING CLINICAL TRIALS
TABLE 26: KEY PHASE 2 ONGOING CLINICAL TRIALS
TABLE 27: KEY PHASE 1 ONGOING CLINICAL TRIALS
TABLE 28: PLANNED CLINICAL TRIALS FOR THE GRANULOMATOSIS AREA
TABLE 29: RECENTLY COMPLETED PHASE 3 CLINICAL TRIALS
TABLE 30: RECENTLY COMPLETED PHASE 2 CLINICAL TRIALS
TABLE 31: RECENTLY COMPLETED PHASE 1 CLINICAL TRIALS
TABLE 32: GLOBAL GRANULOMATOSIS MARKET BY DRUG CLASS (2019-2025)
TABLE 33: GLOBAL GRANULOMATOSIS MARKET BY ROA (2019-2025)
TABLE 34: STRENGTH, DOSAGE AND ROA OF GRANULOMATOSIS DRUGS
TABLE 35: TOP TEN COUNTRIES/TERRITORIES FOR NUMBER OF NEW CASES OF GRANULOMATOSIS PER YEAR
TABLE 36: GLOBAL GRANULOMATOSIS MARKET BY GEOGRAPHY, MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 37: US MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 38: UK MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 39: GERMANY MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 40: FRANCE MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 41: ITALY MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 42: SPAIN MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 43: JAPAN MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 44: CHINA MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 45: INDIA MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 46: BRAZIL MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 47: RUSSIA MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 48: ROW MARKET SIZE (2018), FORECAST (2019-2025)
TABLE 49: LIST OF ESTABLISHED COMPANIES IN THE GRANULOMATOSIS AREA
TABLE 50: LIST OF EMERGING COMPANIES IN THE GRANULOMATOSIS AREA
TABLE 51: COMPETITIVE OPPORTUNITIES, UNIVERSITIES
TABLE 52: COMPETITIVE OPPORTUNITIES, INSTITUTES
(ABOVE MENTIONED TABLES ARE A FEW AMONG THE TOTAL 107 TABLES IN THE REPORT)
LIST OF FIGURES:
FIGURE 1: GLOBAL GRANULOMATOSIS MARKET 2019-2025: MARKET SNAPSHOT
FIGURE 2: GLOBAL GRANULOMATOSIS MARKET BY GEOGRAPHY 2018 V/S 2025
FIGURE 3: GRANULOMATOSIS MARKET BY ROA, 2018
FIGURE 4: GRANULOMATOSIS MARKET BY AGE GROUP, 2018
FIGURE 5: KEY INFLECTION POINTS IN GRANULOMATOSIS MARKET (2015-2030)
FIGURE 6: GRANULOMATOSIS MAJOR FINDINGS
FIGURE 7: MEDICAL EXPENDITURES FOR GRANULOMATOSIS
FIGURE 8: GRANULOMATOSIS EPIDEMIOLOGY (2018), FORECAST (2019-2025)
FIGURE 9: OVERALL DEALS ACTIVITY IN GRANULOMATOSIS AREA
FIGURE 10: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
FIGURE 11: GRANULOMATOSIS DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
FIGURE 12: GRANULOMATOSIS DRUG PIPELINE ANALYSIS BY GEOGRAPHY
FIGURE 13: GRANULOMATOSIS DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
FIGURE 14: GRANULOMATOSIS DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
FIGURE 15: GRANULOMATOSIS DRUG PIPELINE ANALYSIS BY DRUG CLASS
FIGURE 16: ONGOING CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 17: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY HSD
FIGURE 18: RECENTLY COMPLETED CLINICAL TRIALS SPLIT-UP BY MAJOR COMPANIES
FIGURE 19: GRAPHICAL REPRESENTATION OF GLOBAL GRANULOMATOSIS MARKET BY DRUG CLASS
FIGURE 20: GRAPHICAL REPRESENTATION OF GLOBAL GRANULOMATOSIS MARKET BY ROA
FIGURE 21: GRAPHICAL REPRESENTATION, US MARKET SIZE 2018 V/S 2025
FIGURE 22: GRAPHICAL REPRESENTATION, UK MARKET SIZE 2018 V/S 2025
FIGURE 23: GRAPHICAL REPRESENTATION, GERMANY MARKET SIZE 2018 V/S 2025
FIGURE 24: GRAPHICAL REPRESENTATION, FRANCE MARKET SIZE 2018 V/S 2025
FIGURE 25: GRAPHICAL REPRESENTATION, ITALY MARKET SIZE 2018 V/S 2025
FIGURE 26: GRAPHICAL REPRESENTATION, SPAIN MARKET SIZE 2018 V/S 2025
FIGURE 27: GRAPHICAL REPRESENTATION, JAPAN MARKET SIZE 2018 V/S 2025
FIGURE 28: GRAPHICAL REPRESENTATION, CHINA MARKET SIZE 2018 V/S 2025
FIGURE 29: GRAPHICAL REPRESENTATION, INDIA MARKET SIZE 2018 V/S 2025
FIGURE 30: GRAPHICAL REPRESENTATION, BRAZIL MARKET SIZE 2018 V/S 2025
FIGURE 31: GRAPHICAL REPRESENTATION, RUSSIA MARKET SIZE 2018 V/S 2025
FIGURE 32: GRAPHICAL REPRESENTATION, ROW MARKET SIZE 2018 V/S 2025
FIGURE 33: COMPANY FINANCIAL INFORMATION
FIGURE 34: COMPANY SWOT ANALYSIS
(ABOVE MENTIONED FIGURES ARE A FEW AMONG THE TOTAL 53 FIGURES IN THE REPORT)”